Published: December 07, 2012
Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer
LAUSANNE, Switzerland, December 7, 2012 /PRNewswire/ --
Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of
companies with a focus on the development of prescription drugs that target unmet medical
needs and companion diagnostics, announces that Dr. Reddy's Laboratories Ltd. launched
Pamorelin(R) LA in India for the treatment of locally advanced or metastatic,
hormone-dependent prostate cancer on December 3.
Under the terms of the agreement, Dr. Reddy's acquires exclusive marketing and sales
To read the complete release at NewsBlaze,
Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer,
Related PRNewswire Releases News
The delayed healing of the coronary artery following physicians' use of drug eluting stents , which increases patients' risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey ...
Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders
Emerging markets have the greatest potential returns from increasing use of licensed software
The following statement may be attributed to Bryan Gonterman, State President for AT&T Oklahoma.
- Gradually improving macroeconomic conditions, confidence and stock market valuations point toward steady increases in activity
International Minutes, Messages and Megabytes All in One Rate Bundle